Newsfeeds - Spark Newswire

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Tuesday, Oct. 12 2021: COIN, PRLB, SHOP, BYDDY, SE, PYPL, NSTG, TAK, VEEV, VRTX, OPEN

Today, 11:47 PM

Coinbase Global (COIN) - 5,855 Shares Proto Labs (PRLB) - 49,011 Shopify (SHOP) - 15,136 BYD (BYDDY) - 12,440 Sea (SE) - 7,771 PayPal (PYPL) - 26,901 NanoString Technologies (NSTG) - 77,452 Takeda

BYDDY

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Monday, Oct. 11, 2021: SHOP, SE, NSTG, PRLB, IRDM, COIN, NXPI, LC, SMFR, TAK, VEEV, SDGR, EDIT, VRTX, REGN, OPEN

By Benzinga Newsdesk

Today, 11:47 PM

Shopify (SHOP) - 860 Sea (SE) - 5,757 NanoString Technologies (NSTG) - 160,139 Proto Labs (PRLB) - 152,226 Iridium Communications (IRDM)

COIN

8 minute read

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs

By Shanthi Rexaline

Today, 11:47 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)

ABIO

9 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 7, 2021

By Benzinga Insights

Today, 11:47 PM

ALLY

1 minute read

Morgan Stanley Downgrades Takeda Pharmaceutical to Equal-Weight

By Benzinga Newsdesk

Today, 11:47 PM

Morgan Stanley downgrades Takeda Pharmaceutical (NYSE:TAK) from Overweight to Equal-Weight.

TAK

2 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 11:47 PM

ACER

1 minute read

BofA Downgrades Takeda On Suspension Narcolepsy Drug Trials

By Priya Nigam

Today, 11:47 PM

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the suspension of the Phase II trials of its narcolepsy drug candidate TAK-994 due to safety issues.

TAK

1 minute read

12 Health Care Stocks Moving In Wednesday’s Pre-Market Session

By Benzinga Insights

Today, 11:47 PM

ACER

5 minute read

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal

By Shanthi Rexaline

Today, 11:47 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)

ABEO

1 minute read

Takeda Discontinues Two Mid-Stage Narcolepsy Trials

By Vandana Singh

Today, 11:47 PM

Takeda Pharmaceutical Company Limited (NYSE:TAK) has suspended dosing and has decided to stop Phase 2 studies evaluating TAK-994, an investigational oral…

TAK